PR Newswire UK Disclose - LILLY (ELI) & COMPANY - FDA Approves Cymbalta for Treatment of GAD.
For Release: 7 a.m. EST Monday, Feb. 26, 2007
Refer to: David Shaffer (Eli Lilly and Company) 1, 317-651-3710
Ute E. Schmidt (Boehringer Ingelheim) (49) 6132-77-97296
U.S. Regulators Approve CymbaltaA[R] for Treatment of Generalised Anxiety Disorder
INDIANAPOLIS - Feb. 26, 2007 - The U.S.
Related Results
Lilly prepares for Cymbalta launch
Duloxetine lifts arthritis pain, aids cognition.(Psychosomatic Medicine)
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized An…
FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
Duloxetine improves depression, pain, cognition.
Food and Drug Administration (FDA) has
approved the antidepressant CymbaltaA[R] (duloxetine HCl) for the treatment of
generalised anxiety disorder (GAD), Eli Lilly and Company (NYSE: LLY) and
Boehringer Ingelheim announced today.
The approval is based on the results of three randomized, …
Read the rest of this article with a Free Trial at HighBeam Research.
